In-article:

Pfizer: setback on a growth hormone in the USA


(CercleFinance.com) – Pfizer announced on Friday evening that the Food and Drug Administration (FDA) had refused to approve the marketing of somatrogon, a weekly human growth hormone that it developed in collaboration with Opko. Health.

In a press release, the American health giant said it intended to work with the American health authority to find a way to market this long-term treatment intended for children who are stunted.

This long-acting injectable product has already been approved in Japan, Canada and Australia and is currently under review in Europe.

Copyright © 2022 CercleFinance.com. All rights reserved.

Did you like this article ? Share it with your friends with the buttons below.


Twitter


Facebook


LinkedIn


E-mail





Source link -85